# Cizzle Biotechnology Holdings Update and Extension on Put Option with Conduit

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-holdings-update-and-extention-on-put-option-with-conduit/4121126982
- Published: 2023-09-08T07:17:51+01:00
- Author: Anthony Fox

**Cizzle Biotechnology Holdings plc** (LON:CIZ), the UK based diagnostics developer,
has announced a further update regarding the Company’s put option to sell its 5%
economic interest and royalty sharing agreement in the AZD 1656 asset to treat inflammatory
pulmonary and cardiovascular disease to Conduit Pharmaceuticals for a total consideration
of £3.25 million, to be satisfied through the issuance of new shares in Conduit 
and its prospective parent Murphy Canyon Acquisition Corp. (NASDAQ: MURF).

Cizzle announced on 15 August 2023 that Murphy had formally notified its current
shareholders that a special meeting was to be held on 7 September 2023 for Murphy
shareholders to provide their approval for the transaction.  The Board of Cizzle
have now been informed that this meeting has been postponed and will now be held
at 10:00 a.m., Eastern Time**,** **on** Wednesday 20 September 2023**.** As a consequence,
the Option has been extended until 25 October 2023.

Should Cizzle exercise the Option and the Conduit-Murphy Transaction complete, the
Company will hold shares in the Conduit-Murphy merged business, thereafter to be
called Conduit, which will become a publicly traded company on NASDAQ in the USA.
Once issued, the new shares in Conduit to be provided to Cizzle pursuant to the 
exercise of the Option will not be subject to any restrictions.

Cizzle Biotechnology Holdings plc is developing a blood test for the early detection
of lung cancer. The Company is a spin- out from the University of York, founded 
in 2006, around the work of Professor Coverley and colleagues. Its proof-of-concept
prototype test is based on the ability to detect a stable plasma biomarker, a variant
of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved
in DNA replication, and the targeted CIZ1B variant is highly correlated with early-
stage lung cancer. 

Share on:
